ClinicalTrials.gg
CompletedNCT06857617Updated Jan 28, 2026

This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

A Phase 1/2 interventional study of (Part C) MET097 and (Part C) Placebo in Obesity and Overweight, sponsored by Metsera, a wholly owned subsidiary of Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Metsera, a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.
  • Registered 9 months after the study started (first participant enrolled Apr 2024, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing berobenatide in Obesity — 11 open to participants now, 15 under way, 12 of them phase 3. berobenatide · Obesity.

Enrollment
18th of 21
120 · median 258
Started
2024
with 1 other
Phase 1/2
2 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
1 of 21
Metsera, a wholly owned subsidiary of Pfizer

Among the 21 studies testing berobenatide in Obesity, this one is the 18th largest by enrollment, is one of 2 that started in 2024, is one of 2 in phase 1/2, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 21 studies testing berobenatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About berobenatide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing berobenatide in Obesity, or all of them as a file.
02

Study summary

The goal of this Phase 1/2 clinical trial is to assess the safety, tolerability, pharmacokinetics, and efficacy of once-weekly subcutaneous injections of MET097 in otherwise healthy adults with overweight or obesity.

The trial will be conducted in three parts. Part A consists of single ascending dose (SAD) cohorts of MET097 or placebo. Part B consists of multiple ascending dose (MAD) cohorts, with participants treated with five once-weekly doses of MET097 or placebo. In Part C, participants will receive once-weekly doses of MET097 or placebo for 12 weeks, followed by a single dose at 2X or 4X to explore the potential for once-monthly dosing.

03

Conditions studied

  • Obesity and Overweight
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overweight/Obese but otherwise healthy adult male or female with a within 27.0 kg/m2 to 38.0 kg/m2, inclusively
  • At least 18 years of age but not older than 70 years of age
  • Have no diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or , as determined by an Investigator
  • Estimated (eGFR) ≥90 mL/min at the Screening visit

Exclusion criteria

Exclusion Criteria:

  • Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration
  • Seated blood pressure higher than 160/95 mmHg at the Screening visit
  • Elevated resting pulse greater than 100 beats per minute at Screening visit
  • Presence of abnormalities
  • Diagnosis of diabetes (type 1 or type 2)
  • Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration
  • Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome).
  • Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    (Part C) MET097

    Once-weekly subcutaneous injection of MET097 for 13 weeks

    Biological: (Part C) MET097

  • Placebo comparator
    (Part C) Placebo

    Once-weekly subcutaneous injection of Placebo for 13 weeks

    Biological: (Part C) Placebo

Interventions

  • Biological(Part C) MET097

    Participants will receive 13 once-weekly subcutaneous injections of MET097 as follows: * 12 once-weekly doses of 0.6mg followed by a 13th dose of 1.2mg * 12 once-weekly doses of 0.6mg followed by a 13th dose of 2.4 mg * 12 once-weekly doses of 0.8 mg followed by a 13th dose of 1.6 mg * 12 once-weekly doses of 0.8 mg followed by a 13th dose of 3.2 mg * 12 once-weekly doses of 1.0 mg followed by a 13th dose of 2.0 mg * 12 once-weekly doses of 1.0 mg followed by a 13th dose of 4.0 mg * 12 once-weekly doses of 1.2 mg followed by a 13th dose of 2.4 mg * 12 once-weekly doses of 1.2 mg followed by a 13th dose of 4.8 mg * Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 2.4mg * Titration regimen of 0.4mg/0.8mg/1.2mg with 4 doses at each dose-level, followed by a 13th dose of 4.8mg

  • Biological(Part C) Placebo

    Participants will receive 13 once-weekly subcutaneous injections of matching placebo

06

What researchers measure

Primary outcomes

  1. (Part C) Percent change from baseline in body weight at Week 12 (Day 85).

    Time frame: Day 1 (Week 0) to Day 85 (Week 12)

Secondary outcomes

  1. (Part C) To characterize the maximum observed concentration (Cmax).

    Time frame: Day 1 (Week 0) to Day 160 (Week 31)

  2. (Part C) To characterize the time of maximum observed concentration (Tmax).

    Time frame: Day 1 (Week 0) to Day 160 (Week 31)

  3. (Part C) To characterize the area under the concentration versus time curve (AUC).

    Time frame: Day 1 (Week 0) to Day 160 (Week 31)

  4. (Part C) To characterize the elimination half-life (t1/2).

    Time frame: Day 1 (Week 0) to Day 160 (Week 31)

  5. (Part C) Occurrence of treatment-emergent adverse events (TEAEs) through Week 12.

    Time frame: Day 1 (Week 0) to Day 85 (Week 12)

  6. (Part C) Occurrence of TEAEs following the 13th dose.

    Time frame: Day 85 (Week 12) to Day 160 (Week 31)

07

Study locations

3 sites
  • Research Site MET097 23-101-002
    Anaheim, California 92801, United States
  • Research Site MET097 23-101-003
    Cypress, California 90630, United States
  • Research Site MET097 23-101-001
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jan 2025, 9 months.

Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2025
First posted
Mar 4, 2025
StartActual
Apr 1, 2024
Primary completionActual
Jan 3, 2025
CompletionActual
Mar 15, 2025
Results delay requested
Jan 2, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06857617
Responsible party
Sponsor
First posted
Mar 4, 2025
Start date
Apr 1, 2024
Primary completion
Jan 3, 2025
Completion
Mar 15, 2025
Last update
Jan 28, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Berobenatide

Start the discussion